Uptake Medical announced it has received the CE (Conformit‚ Europ‚enne) Mark for the InterVapor System. — the first
endoscopic lung volume reduction system for the treatment of severe emphysema that uses the body’s natural healing processes without leaving foreign materials behind. The CE Mark will allow Uptake Medical to commercialize InterVapor in key markets within the European community.
InterVapor is a minimally invasive procedure which treats hyperinflated parts of the lungs with heated water vapor. InterVapor triggers the body’s natural healing process, gradually reducing the treated portion of the lungs and increasing the ability to breathe more fully. Unlike other approaches to lung volume reduction, InterVapor requires no foreign materials to be left behind in the lung which may require additional procedures.
This announcement coincides with the presentation of the six-month results from a worldwide, multi-center VAPOR trial at the European Respiratory Society Annual Congress on Sept. 25 in Amsterdam. The clinical trial data shows significant improvement in breathing capacity, shortness of breath, exercise capacity and quality of life.
